Iodine I 131 Tositumomab
Sponsors
GlaxoSmithKline, Fred Hutchinson Cancer Center, University of Michigan Rogel Cancer Center
Conditions
Anaplastic Large Cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueLymphoma, FollicularLymphoma, Large-Cell, FollicularLymphoma, Non-HodgkinLymphoma, Small Cleaved-Cell, FollicularMultiple Myeloma
Phase 1
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
CompletedNCT00062894
Start: 2003-04-30End: 2007-04-30Updated: 2007-09-17
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
CompletedNCT00110071
Start: 2005-01-31Updated: 2014-08-06
Phase 2
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
CompletedNCT00073918
Start: 1999-02-28End: 2011-10-02Updated: 2017-08-18
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
CompletedNCT00135200
Start: 2005-08-31End: 2024-09-04Updated: 2025-04-30